1. Home
  2. GPRK vs ALT Comparison

GPRK vs ALT Comparison

Compare GPRK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPRK
  • ALT
  • Stock Information
  • Founded
  • GPRK 2002
  • ALT 1997
  • Country
  • GPRK Colombia
  • ALT United States
  • Employees
  • GPRK N/A
  • ALT N/A
  • Industry
  • GPRK Oil & Gas Production
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPRK Energy
  • ALT Health Care
  • Exchange
  • GPRK Nasdaq
  • ALT Nasdaq
  • Market Cap
  • GPRK 351.5M
  • ALT 339.0M
  • IPO Year
  • GPRK N/A
  • ALT N/A
  • Fundamental
  • Price
  • GPRK $6.74
  • ALT $4.08
  • Analyst Decision
  • GPRK Buy
  • ALT Strong Buy
  • Analyst Count
  • GPRK 1
  • ALT 6
  • Target Price
  • GPRK $11.00
  • ALT $18.20
  • AVG Volume (30 Days)
  • GPRK 474.8K
  • ALT 6.6M
  • Earning Date
  • GPRK 08-06-2025
  • ALT 08-07-2025
  • Dividend Yield
  • GPRK 8.74%
  • ALT N/A
  • EPS Growth
  • GPRK N/A
  • ALT N/A
  • EPS
  • GPRK 1.51
  • ALT N/A
  • Revenue
  • GPRK $630,771,000.00
  • ALT $20,000.00
  • Revenue This Year
  • GPRK N/A
  • ALT N/A
  • Revenue Next Year
  • GPRK $5.80
  • ALT $507,435.66
  • P/E Ratio
  • GPRK $4.45
  • ALT N/A
  • Revenue Growth
  • GPRK N/A
  • ALT N/A
  • 52 Week Low
  • GPRK $5.66
  • ALT $2.90
  • 52 Week High
  • GPRK $11.72
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • GPRK 45.25
  • ALT 40.20
  • Support Level
  • GPRK $6.56
  • ALT $4.03
  • Resistance Level
  • GPRK $7.14
  • ALT $4.39
  • Average True Range (ATR)
  • GPRK 0.25
  • ALT 0.23
  • MACD
  • GPRK -0.01
  • ALT 0.03
  • Stochastic Oscillator
  • GPRK 21.34
  • ALT 18.43

About GPRK Geopark Ltd

GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: